1. Home
  2. CYTK vs BDC Comparison

CYTK vs BDC Comparison

Compare CYTK & BDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • BDC
  • Stock Information
  • Founded
  • CYTK 1997
  • BDC 1902
  • Country
  • CYTK United States
  • BDC United States
  • Employees
  • CYTK N/A
  • BDC N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • BDC Telecommunications Equipment
  • Sector
  • CYTK Health Care
  • BDC Telecommunications
  • Exchange
  • CYTK Nasdaq
  • BDC Nasdaq
  • Market Cap
  • CYTK 4.6B
  • BDC 5.1B
  • IPO Year
  • CYTK 2004
  • BDC 1993
  • Fundamental
  • Price
  • CYTK $49.76
  • BDC $129.38
  • Analyst Decision
  • CYTK Buy
  • BDC Strong Buy
  • Analyst Count
  • CYTK 15
  • BDC 5
  • Target Price
  • CYTK $75.57
  • BDC $135.20
  • AVG Volume (30 Days)
  • CYTK 2.7M
  • BDC 277.3K
  • Earning Date
  • CYTK 11-05-2025
  • BDC 10-30-2025
  • Dividend Yield
  • CYTK N/A
  • BDC 0.15%
  • EPS Growth
  • CYTK N/A
  • BDC 16.75
  • EPS
  • CYTK N/A
  • BDC 5.50
  • Revenue
  • CYTK $85,738,000.00
  • BDC $2,617,821,000.00
  • Revenue This Year
  • CYTK $330.96
  • BDC $9.55
  • Revenue Next Year
  • CYTK $73.41
  • BDC $5.01
  • P/E Ratio
  • CYTK N/A
  • BDC $23.46
  • Revenue Growth
  • CYTK 2635.74
  • BDC 12.93
  • 52 Week Low
  • CYTK $29.31
  • BDC $83.18
  • 52 Week High
  • CYTK $59.39
  • BDC $133.77
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 63.01
  • BDC 51.94
  • Support Level
  • CYTK $49.22
  • BDC N/A
  • Resistance Level
  • CYTK $53.58
  • BDC $133.74
  • Average True Range (ATR)
  • CYTK 2.54
  • BDC 2.59
  • MACD
  • CYTK 0.29
  • BDC -4.94
  • Stochastic Oscillator
  • CYTK 76.53
  • BDC 96.74

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About BDC Belden Inc

Belden designs, manufactures, and markets advanced networking, connectivity, and cable solutions for industrial automation, smart buildings, and broadcast markets. Their portfolio includes cables, connectors, and networking equipment, enabling secure, reliable data transmission for applications in data centers, healthcare, education, hospitality, and more.

Share on Social Networks: